The PSA Screening for HIM Act (H.R. 1826/S. 2821) would remove out-of-pocket costs for prostate cancer screening for those at highest risk for the disease.
ACS CAN Comments on Draft FDA Guidance on Clinical Trial Diversity Plans
June 13, 2022
ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on the Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials Draft Guidance for Industry.